• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
H1N1 Vaccines - Global Strategic Business Report Product Image

H1N1 Vaccines - Global Strategic Business Report

  • ID: 1227784
  • March 2015
  • Region: Global
  • 137 Pages
  • Global Industry Analysts, Inc

This report analyzes the worldwide markets for H1N1 Vaccines in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020.

Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 33 companies including many key and niche players such as -

- Abbott Laboratories
- CPL Biologicals Pvt. Ltd.
- bioCSL
- GlaxoSmithKline Plc
- MedImmune, LLC

Note: Product cover images may vary from those shown

H1N1 VACCINES

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW
Resurgence of the H1N1 Virus
A Glimpse of the 2009 H1N1 Pandemic Outbreak, and the Post- Pandemic Phase
Efforts to Face Potential Pandemics
Competitive Scenario
H1N1 Influenza Vaccines and Manufacturers

2. GROWTH DRIVERS/RESTRAINTS/ CHALLENGES
Key Growth Drivers
Consumer Awareness Drives Market Growth in Developed Regions
Emerging Economies Offer Strong Potential
Threat of Antigenic Shift of H1N1 Virus Lingers
Key Growth Inhibitors
Requirement of Huge Capital and Large-Scale Investments
Stringent Regulatory Scenario
High Competition Lowers Profit Margins
Challenges Facing Healthcare Industry in Tackling Pandemics
Cumbersome Production Process, New Technologies Come to Rescue
Inefficiencies in Vaccine Distribution: A Cause of Concern
Shorter Lifecycle of Pandemic Influenza
Market Trends
Antigenic Shift of Virus Unlocks Possibilities for New Seasonal Influenza Vaccines
Quadrivalent Vaccines
A Whole New Generation of Seasonal Influenza Vaccines
Innovations in Vaccine Technology to Drive the Effort for a Universal Influenza Vaccine
Safety Concerns of Influenza Vaccines Abate
H1N1 Vaccine Sourced from Tobacco Plants

3. AN INSIGHT INTO THE GLOBAL VACCINES MARKET
Vaccines Market to Witness Robust Increase in Sales Driven by Robust Demand
Pneumococcal and Pediatric Multivalent Vaccines Dominate Sales
Table 1: Global Vaccines Market by Category (2014): Percentage Breakdown of Value Sales for Adult Booster, Hepatitis, HPV, Influenza, Meningococcal, Pediatric Multivalent, Pneumococcal, Rotavirus, and Shingles (includes corresponding Graph/Chart)
Competitive Scenario
Table 2: Global Vaccines Market by Leading Manufacturer (2014): Percentage Market Share Breakdown of Value Sales for Astra Zeneca, GlaxoSmithKline, Merck & Co, Pfizer, Sanofi Pasteur, and Others (includes corresponding Graph/Chart)

4. H1N1 PANDEMIC
A HISTORICAL PERSPECTIVE
Influenza A (H1N1) 2009: The Global Pandemic
Table 3: Global Death Toll from 2009 A H1N1 (2009-2012) (includes corresponding Graph/Chart)
Table 4: Mortality Rates of Major Influenza Pandemics Over the Last 100 Years (includes corresponding Graph/Chart)
Economic Impact of H1N1 Pandemic in Retrospect
Healthcare & Pharmaceuticals
Pork & Pork Products
Airlines, Tourism & Hospitality
Hand Sanitizers
H1N1 Influenza Diagnostic Tests
Table 5: Global Laboratory Rapid Testing by Leading Player (2014): Percentage Market Share Breakdown of Value Sales for Alere, Quidel, Meridian Bioscience, Beckman Coulter/Danaher, OraSure and Others (includes corresponding Graph/Chart)

5. H1N1 INFLUENZA
AN OVERVIEW
Influenza Virus: A Quick Primer
Symptoms and Characteristics
Types of Influenza
Influenza A Virus
Influenza A (H1N1) Virus
Different Names, in Different Countries
Symptoms and Risk Factors
The Pandemic Life-Cycle
Seasonal Influenza vis-à-vis H1N1 Flu
How H1N1 Is Diagnosed?
Prevention and Vaccination Against H1N1
Prevention
Vaccination
Vaccine Virus Selection for the 2015-2016 Influenza Season
WHO Recommended Virus Strains for Seasonal Influenza Vaccines for Northern Hemisphere for 2015-2016
WHO Recommended Virus Strains for Seasonal Influenza Vaccines for Southern Hemisphere for 2015-2016
How is H1N1 Vaccine Prepared?
Egg-Based Production Process
Cell Culture-Based Technology
Recombinant Technology
Side Effects of H1N1 Vaccine
Primary Targets for Vaccination
Adverse Group for Vaccination
Treatment for Swine-Flu Infected Individuals
Anti-Virals for Pandemic (H1N1) 2009 Infection
Recommended Dosage of Anti-Virals
Rapivab (Peramivir)
The IV Flu Drug

6. REGULATORY APPROVALS
FDA Approves Rapivab by BioCryst Pharmaceuticals
GSK Obtains Marketing Authorization for Quadrivalent Influenza Vaccine in the UK and Germany
Sanofi Pasteur’s Review Application for Quadrivalent Influenza Vaccine Accepted by EU
MedImmune Announces FDA Approval of First Quadrivalent Flu Vaccine
Novartis Announces FDA Approval for Cell-Culture Derived Vaccine
GlaxoSmithKline Obtains FDA Approval for FLUARIX® QUADRIVALENT
Tianyuan Receives GMP Certification for Influenza and H1N1 Vaccine

7. PRODUCT LAUNCHES
Serum Institute of India to Launch NasoVacS
Bharat Biotech to Produce Swine Flu Vaccine in Bulk
Vaxart Announces Positive Trials of its H1N1
Tablet Vaccine
A*Star and Cytos Biotechnology Collaborate for H1N1 Vaccine
VABIOTECH Develops Vaccines for A/H1N1 and A/H5N1 Viruses
Focus Diagnostics and 3M Unveil Simplexa™ Test on 3M™ Integrated Cycler

8. RECENT INDUSTRY ACTIVITY
GSK Acquires GlycoVaxyn AG
Baxter to Divest Vero cell Vaccine Technogy and Assets to Nanotherapeutics
Novartis to Divest Influenza Vaccines Business to CSL
CALIXAR and VirPath Develop Novel Manufacturing Process for Influenza Vaccines
bioCSL Restarts Manufacture of Influenza Vaccine
Novartis Begins Shipment of Seasonal Influenza Vaccines to US
bioCSL Obtains Government Contracts for Vaccine Distribution
InGen Biosciences Partners with Quidel and Diagnostic Hybrids

9. FOCUS ON SELECT GLOBAL PLAYERS
Abbott Laboratories (US)
CPL Biologicals Pvt. Ltd. (India)
bioCSL (Australia)
GlaxoSmithKline Plc. (UK)
MedImmune, LLC. (US)
Novartis AG (Switzerland)
Sanofi Pasteur, SA (France)
Sinovac Biotech Ltd. (China)
Zydus Cadila (India)

10. GLOBAL MARKET PERSPECTIVE
Table 6: World Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region
US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 7: World Historic Review for H1N1 Vaccines by Geographic Region
US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)
Table 8: World 12-year Analysis for H1N1 Vaccines by Geographic Region
Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for the Years 2009, 2015 and 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES
A.Market Analysis
‘Swine Flu’ Strain Returns in the 2013-14 Season
Major H1N1 Vaccines Available in the US and Canada
US FDA-Approved Influenza Vaccines with 2009 H1N1 Virus Strain Indicated for 2014-2015 Flu Season
US FDA-Approved Quadrivalent Vaccines Incorporating H1N1 Strain for Influenza Type A and B (2014-15)
Preparations Authorized by Health Canada for Influenza, including H1N1, in Canada (2014-15 season)
Medicare and Medicaid Services for Influenza in the US
Table 9: CDC Price List for Pediatric Influenza Vaccines in Basic Package: 2015-2016
Table 10: CDC Price List for Adult Influenza Vaccines in Basic Package: 2015-2016
A Historical Perspective on the H1N1 Pandemic in North America
First Case of H1N1 Infection Reported in Mexico
Swine Flu Spreads to the United States
H1N1 Pandemic Linked to Delay in Vaccine Administration
Canadian Government’s H1N1 Mass Vaccination Campaign
Product Approvals & Launches
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 11: The US Recent Past, Current & Future Analysis for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 12: The US Historic Review for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

2. EUROPE
A.Market Analysis
H3N2 Viruses Predominate in the 2014/15 Season; H1N1 Still in Circulation
An Insight into European Influenza Vaccination Scenario
Cell-based Vaccine Production Remains Nascent, Egg-based Widely Used
Major Influenza Vaccines Available in European Union Member Countries
Major H1N1 Flu Vaccines Available in Select East European Markets
ECDC Proposes New Influenza Vaccination Strategy
Immunization of High-Risk Demographics
Protecting Children, Adolescents, and Young Adults
Stemming the Spread of Infection in Public Centers
EU Welcomes Quadrivalent LAIVs
Safety Concerns of Influenza Vaccines Abate
Historical Perspective on the H1N1 Pandemic in Europe
Product Approvals & Launches
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 13: European Recent Past, Current & Future Analysis for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 14: European Historic Review for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

3. ASIA-PACIFIC
A.Market Analysis
2014-15: Deadliest Swine Flu Season in India Since 2009
Leading Influenza H1N1 Vaccine Brands Available in Select Asia-Pacific Markets
Historical Perspective on The Outbreak of H1N1 Pandemic In 2009 In Select Regions
Japan
South Korea
Taiwan
Malaysia
Philippines
New Zealand
India
China
Hong Kong
Singapore
Australia
Product Approvals & Launches
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 15: Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 16: Asia-Pacific Historic Review for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

4. REST OF THE WORLD
Market Analysis
Table 17: Rest of World Recent Past, Current & Future Analysis for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 18: Rest of World Historic Review for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 33 (including Divisions/Subsidiaries 36)

The United States (13)
Japan (2)
Europe (8)
- France (3)
- The United Kingdom (2)
- Rest of Europe (3)
Asia-Pacific (Excluding Japan) (13)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Pfizer, Inc. Grünenthal GmbH GlaxoSmithKline PLC Abbott Laboratories Ltd. Roche Diagnostics Ltd. Novo Nordisk A/S